Skip to main navigation Skip to search Skip to main content

Course of ante-and postnatal depressive symptoms related to mothers' HPA axis regulation

  • Heidemarie Laurent
  • , Sherryl H. Goodman
  • , Zachary N. Stowe
  • , Meeka Halperin
  • , Faaiza Khan
  • , Dorianne Wright
  • , Benjamin W. Nelson
  • , D. Jeffrey Newport
  • , James C. Ritchie
  • , Catherline Monk
  • , Bettina Knight

Research output: Contribution to journalArticlepeer-review

Abstract

Given high health costs of depression during pregnancy and the first postnatal year, it is important to understand mechanisms involved in the emergence and perpetuation of symptoms during this time. In a series of 2 studies, we aim to clarify bidirectional relations between mothers' physiological stress regulation-stress-related activation of the hypothalamic-pituitary-adrenal (HPA) axis-and their course of depressive symptoms. In Study 1, 230 pregnant women recruited from a women's mental health program gave 3 saliva samples in the context of psychosocial stress at 24, 30, and 36-weeks gestation. They self-reported depressive symptoms across the three trimesters of pregnancy and first year postpartum. Multilevel models revealed women with elevated salivary cortisol during pregnancy showed a course of escalating ante- and postnatal symptoms, implicating HPA hyperactivation as a precursor to worsening mood problems. In Study 2, 54 mothers from a community sample self-reported depressive symptoms at 3, 6, 12, and 18 months postnatal. At 18 months, they participated in a dyadic stress task with their infant and gave 4 saliva samples for cortisol assay. For mothers with a lifetime depression diagnosis, an escalating course of postnatal symptoms predicted a higher, flatter cortisol response profile. Together, the results of these studies suggest that for high-risk mothers, a trajectory of worsening depression may both follow from and give rise to neuroendocrine stress hyperactivation. These findings suggest greater attention is warranted to course of depressive symptoms across the ante- and postnatal period, rather than symptom levels at any given time, to characterize health risks.

Original languageEnglish (US)
Pages (from-to)404-416
Number of pages13
JournalJournal of Abnormal Psychology
Volume127
Issue number4
DOIs
StatePublished - May 1 2018
Externally publishedYes

Funding

D. Jeffrey Newport has received research support from Eli Lilly, Glaxo SmithKline, Janssen, the National Alliance for Research on Schizophrenia and Depression (NARSAD), the National Institutes of Health (NIH), Takeda Pharmaceuticals, and Wyeth. He has served on speakers’ bureaus and/or received honoraria from Astra-Zeneca, Eli Lilly, Glaxo SmithKline, Pfizer, and Wyeth. He has served on advisory boards for Glaxo SmithKline, Janssen, and Sage Therapeutics. He has never served as a consultant to any biomedical or pharmaceutical corporations. Neither he nor family members have ever held equity positions in biomedical or pharmaceutical corporations. Zachary N. Stowe has served as a study clinician for Janssen Pharmaceuticals. Bettina Knight has a son employed by GlaxoSmith Kline and has stock options in the company. D. Jeffrey Newport has received research support from Eli Lilly, Glaxo SmithKline, Janssen, the National Alliance for Research on Schizophrenia and Depression (NARSAD), the National Institutes of Health (NIH), Takeda Pharmaceuticals, and Wyeth. He has served on speakers' bureaus and/or received honoraria from Astra-Zeneca, Eli Lilly, Glaxo SmithKline, Pfizer, and Wyeth. He has served on advisory boards for Glaxo SmithKline, Janssen, and Sage Therapeutics. He has never served as a consultant to any biomedical or pharmaceutical corporations. Neither he nor family members have ever held equity positions in biomedical or pharmaceutical corporations. Zachary N. Stowe has served as a study clinician for Janssen Pharmaceuticals. Bettina Knight has a son employed by GlaxoSmith Kline and has stock options in the company.

Funders
Glaxo Smithkline
GlaxoSmith Kline
Author National Institutes of Health National Institutes of Health National Institutes of Health National Institutes of Health The Bev Hartig Huntington's Disease Foundation National Institutes of Health
Eli Lilly and Company
Pfizer
Janssen Biotech
Takeda Pharmaceuticals North America
Janssen Pharmaceuticals
National Alliance for Research on Schizophrenia and Depression
Sage Therapeutics

    Keywords

    • Antenatal and postnatal
    • Cortisol
    • Depression
    • HPA
    • Mothers

    ASJC Scopus subject areas

    • Psychiatry and Mental health
    • Biological Psychiatry

    Fingerprint

    Dive into the research topics of 'Course of ante-and postnatal depressive symptoms related to mothers' HPA axis regulation'. Together they form a unique fingerprint.

    Cite this